Human gelatin thrombin matrix with rifampin for the treatment of prosthetic vascular graft infections.
Bioabsorbable antibiotics
Expanded polytetrafluoroethylene grafts
HGTM
Human thrombin-gelatin matrix
Prosthetic graft infections
Rifampin
VGI
Vascular graft infection
Journal
Journal of vascular surgery cases and innovative techniques
ISSN: 2468-4287
Titre abrégé: J Vasc Surg Cases Innov Tech
Pays: United States
ID NLM: 101701125
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
07
07
2023
accepted:
23
10
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
epublish
Résumé
We aim to describe and report on a novel graft preservation technique using a human gelatin thrombin matrix with rifampin for the treatment of vascular graft infections. Eight patients with vascular graft infections were included, one with bilateral infections, for a total of nine cases from January 2016 through June 2021. All the patients underwent wound exploration and placement of human gelatin thrombin matrix with rifampin. No deaths or allergic reactions had been reported at the 30-day follow-up, with only one major amputation. The graft and limb salvage rates were 77.8% at the 1-year follow-up. The mean time to a major amputation was 122 days, and the mean time to graft excision was 30 days.
Identifiants
pubmed: 38130367
doi: 10.1016/j.jvscit.2023.101365
pii: S2468-4287(23)00274-5
pmc: PMC10731601
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101365Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
None.